Centanafadine's ADHD approval, the MDMA NDA resubmission, DT120 phase 3 wins, and the FDA psychedelic hearing headline Q3 2026 psychiatry news.
News|Articles|April 8, 2026
Q1 2026 Recap: Psychiatry News and Updates
Author(s)Chelsie Derman
Fact checked by: Tim Smith
FDA approvals, at-home neuromodulation, phase 3 psychedelic data, and rising AI therapy use impacted the psychiatry field in the first quarter of 2026.
Advertisement
Advertisement
The first quarter of 2026 brought regulatory approvals, late-stage psychedelic data, and increased use of at-home neuromodulation and artificial intelligence–supported mental health tools that reflected rapid change across psychiatry.
Related to this article
Here, we review the top psychiatry news in September 2026, from DT120's second Breakthrough Therapy designation to the FDA psychedelic hearing.
Nephrology in Q3 2026: FDA approvals for atacicept, iptacopan, finerenone, and obinutuzumab, plus 2-year IgAN data and CKD screening.
Q3 2026 dermatology recap: FDA approvals in dermatomyositis, adolescent alopecia areata, and sBCC, plus new psoriasis and vitiligo findings.
Approved US PFIC drugs treat pruritus. The researcher behind a therapy targeting BSEP on diagnosis, data, and what comes next.
Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.
Hematology in September 2026: ASH raises ferritin thresholds for iron deficiency, plus marstacimab in hemophilia and curative SCD care.
Strong recommendations cover carvedilol or banding for varices, semiannual HCC surveillance, vaccines, and smoking cessation.
Advertisement
Advertisement